Objective: To explore the association between Enzyme Replacement Therapy (ERT), clinical characteristics and the rate of progression of White Matter Hyperintensities (WMHs) in Fabry disease (FD) patients. Methods: Patients with a confirmed diagnosis of FD, aged >18 years, participating in an existing FD observational study (NCT00196742), with at least two serial MRI brain scans at least 2 years apart for the period between December 2006 and August 2016 were included in this cohort study. Total WMH volume was estimated for each image using a semi-automated procedure. We performed linear regression to calculate the primary outcome measure of WMH change rate for each participant. Associations between ERT, clinical characteristics and the prima...
Fabry disease (FD) is an X-linked lysosomal storage disorder with multi-system involvement including...
Background and Purpose: Data on the prevalence of Fabry disease in patients with central nervous sys...
Background: Enzyme replacement therapy (ERT) with recombinant human a-galactosidase has been availab...
Objective: To explore the association between Enzyme Replacement Therapy (ERT), clinical characteris...
Background and aim: It is unclear which patients with Fabry disease (FD) are at risk for progression...
Background: Fabry disease (FD) is a rare lysosomal storage disorder that might result in, amongst ot...
Despite enzyme replacement therapy, disease progression is observed in patients with Fabry disease. ...
The long-term effects of enzyme-replacement therapy (ERT) in Fabry disease are unknown. Thus, the ai...
<div><p>Despite enzyme replacement therapy, disease progression is observed in patients with Fabry d...
BACKGROUND: We analysed 5-year treatment with agalsidase alfa enzyme replacement therapy in patients...
Cerebral involvement is common in Fabry disease (FD). This thesis aimed to incorporate patients’ ill...
To assess structural and metabolic brain changes in subjects affected by Fabry disease (FD) or carry...
Background. In Fabry disease, progressive glycolipid ac-cumulation leads to organ damage and early d...
Outcomes from 5 years of treatment with agalsidase alfa enzyme replacement therapy (ERT) for Fabry d...
Background: Enzyme replacement therapy (ERT) slows disease progression of Fabry disease (FD), especi...
Fabry disease (FD) is an X-linked lysosomal storage disorder with multi-system involvement including...
Background and Purpose: Data on the prevalence of Fabry disease in patients with central nervous sys...
Background: Enzyme replacement therapy (ERT) with recombinant human a-galactosidase has been availab...
Objective: To explore the association between Enzyme Replacement Therapy (ERT), clinical characteris...
Background and aim: It is unclear which patients with Fabry disease (FD) are at risk for progression...
Background: Fabry disease (FD) is a rare lysosomal storage disorder that might result in, amongst ot...
Despite enzyme replacement therapy, disease progression is observed in patients with Fabry disease. ...
The long-term effects of enzyme-replacement therapy (ERT) in Fabry disease are unknown. Thus, the ai...
<div><p>Despite enzyme replacement therapy, disease progression is observed in patients with Fabry d...
BACKGROUND: We analysed 5-year treatment with agalsidase alfa enzyme replacement therapy in patients...
Cerebral involvement is common in Fabry disease (FD). This thesis aimed to incorporate patients’ ill...
To assess structural and metabolic brain changes in subjects affected by Fabry disease (FD) or carry...
Background. In Fabry disease, progressive glycolipid ac-cumulation leads to organ damage and early d...
Outcomes from 5 years of treatment with agalsidase alfa enzyme replacement therapy (ERT) for Fabry d...
Background: Enzyme replacement therapy (ERT) slows disease progression of Fabry disease (FD), especi...
Fabry disease (FD) is an X-linked lysosomal storage disorder with multi-system involvement including...
Background and Purpose: Data on the prevalence of Fabry disease in patients with central nervous sys...
Background: Enzyme replacement therapy (ERT) with recombinant human a-galactosidase has been availab...